News on bioinformatics, software, genome analysis, variant classification, and IT in genetics, genomics, and molecular diagnostics.
With nearly $100 million in new investments since last year, the San Francisco-based informatics firm looks to ramp up its precision oncology partnerships.
The companies will use their respective technologies and expertise to identify multi-gene biomarkers that can be used in cancer drug discovery.
RenalytixAI will provide financial support to the University of Utah in the form of sponsored research into kidney disease progression, treatment, and biomarkers.
Genomenon will integrate its AI-driven Mastermind search engine into the BC|Genome and BC|Insight platforms.
Using technology rooted in pharmacogenomics testing for medical cannabis, the firm claims it can predict immune response to SARS-CoV-2 and test biomarkers for pharma.
